Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript Summary
Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript:
以下是神經分泌生物科學公司(NBIX)2024年第三季度業績會成績單摘要:
Financial Performance:
金融業績:
Neurocrine Biosciences reported a strong Q3 with INGREZZA delivering $613 million in sales, reflecting year-over-year growth and an increase in guidance range to $2.3 to $2.32 billion.
The company announced a $300 million share repurchase plan and acknowledged significant growth of its multibillion-dollar franchise.
Q3 financials support ongoing investment in pipeline development and strategic plans.
神經分泌生物科學報告第三季度強勁,INGREZZA銷售額達到61300萬美元,反映出同比增長,並將指導範圍提高至23.2億至2.3億美元。
該公司宣佈了30000萬美元的股份回購計劃,並承認其數十億美元特許經營的顯著增長。
第三季度財務數據支持對管道發展和戰略計劃的持續投資。
Business Progress:
業務進展:
Neurocrine is positioned for future growth with a focus on the launches of INGREZZA and Crinecerfont, both potentially serving large patient populations.
Advanced multiple pipeline projects including NBI-'845 and NBI-'568 into Phase III trial preparations, with data readouts and program initiations expected next year.
Expanded salesforce in psychiatry and long-term care to capture more market share, with executives expressing confidence in ongoing team performance and pipeline productivity.
神經分泌已做好未來增長的準備,重點放在INGREZZA和Crinecerfont的推出上,兩者潛在服務於大量患者人群。
先進的多管道項目包括將NBI-'845和NBI-'568推進到第三階段試驗準備階段,數據披露和項目啓動預計在明年進行。
擴大賽富時在精神病學和長期護理領域的業務,以獲取更多市場份額,高管對團隊績效和管道生產力表示信懇智能。
Opportunities:
機會:
The treatment potential of INGREZZA for Tardive Dyskinesia and Huntington's disease Chorea, coupled with strategic salesforce expansions, presents significant market capture opportunities.
Crinecerfont is nearing approval with a strong market positioning for CAH treatment, poised to dominate a market that hasn't seen new treatments in 70 years.
INGREZZA在遲發性運動障礙和亨廷頓病脈鼓的治療潛力,加上戰略賽富時擴張,提供了重要的市場佔有機遇。
Crinecerfont即將獲得批准,在腎上腺增生症治療領域具有強大的市場定位,有望主導一個70年未見新療法的市場。
Risks:
風險:
The company's shares are deemed to be trading at a 'significant discount,' reflecting possible market undervaluation, which might affect investor sentiment and capital allocation efficiency.
Pressure from competitive dynamics in the TD market and upcoming market entries such as Crinecerfont might impact pricing and market share.
公司股價被認爲正在以「顯著折扣」交易,反映了可能的市場低估,這可能影響投資者情緒和資本配置效率。
來自遲發性運動障礙市場競爭動態和即將進入市場的Crinecerfont的壓力可能影響定價和市場份額。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。